1 week Ago By ABMN Staff
Norges Bank purchased a new stake in Inspire Medical Systems, Inc. ( NYSE:INSP – Free Report ) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 57,617 shares of the company’s stock, valued at approximately $10,681,000.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. lifted its holdings in shares of Inspire Medical Systems by 885.
7% during the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company’s stock worth $26,000 after buying an additional 124 shares in the last quarter.
Harbour Investments Inc. raised its stake in Inspire Medical Systems by 101.0% in the 4th quarter.
Harbour Investments Inc. now owns 197 shares of the company’s stock worth $37,000 after purchasing an additional 99 shares in the last quarter. AlphaQuest LLC boosted its holdings in Inspire Medical Systems by 7,275.
0% in the 4th quarter. AlphaQuest LLC now owns 295 shares of the company’s stock valued at $55,000 after purchasing an additional 291 shares during the period. Smartleaf Asset Management LLC grew its position in shares of Inspire Medical Systems by 178.
9% during the 4th quarter. Smartleaf Asset Management LLC now owns 357 shares of the company’s stock worth $66,000 after purchasing an additional 229 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Inspire Medical Systems by 37.
3% during the fourth quarter. Nisa Investment Advisors LLC now owns 368 shares of the company’s stock worth $68,000 after purchasing an additional 100 shares during the period. 94.
91% of the stock is owned by institutional investors. Analysts Set New Price Targets INSP has been the subject of several recent research reports. Piper Sandler cut their price target on Inspire Medical Systems from $260.
00 to $233.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $260.
00 target price on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Wells Fargo & Company decreased their price target on Inspire Medical Systems from $198.00 to $195.
00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 11th. Stifel Nicolaus cut their price objective on shares of Inspire Medical Systems from $200.00 to $190.
00 and set a “hold” rating for the company in a research report on Tuesday, January 21st. Finally, Truist Financial decreased their target price on shares of Inspire Medical Systems from $250.00 to $235.
00 and set a “buy” rating on the stock in a report on Tuesday, February 11th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.
com, Inspire Medical Systems presently has a consensus rating of “Moderate Buy” and a consensus target price of $226.70. Inspire Medical Systems Trading Down 5.
4 % INSP stock opened at $141.63 on Wednesday. The firm has a 50-day moving average price of $173.
26 and a 200-day moving average price of $186.81. Inspire Medical Systems, Inc.
has a 12 month low of $123.00 and a 12 month high of $257.40.
The stock has a market capitalization of $4.21 billion, a P/E ratio of 81.86, a price-to-earnings-growth ratio of 2.
86 and a beta of 1.39. Inspire Medical Systems ( NYSE:INSP – Get Free Report ) last released its quarterly earnings data on Monday, February 10th.
The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.74 by $0.
41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.
19%. As a group, equities analysts predict that Inspire Medical Systems, Inc. will post 2.
16 EPS for the current fiscal year. Insider Activity In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $183.
50, for a total value of $4,694,664.00. Following the completion of the transaction, the insider now directly owns 7,259 shares in the company, valued at approximately $1,332,026.
50. This represents a 77.90 % decrease in their position.
The sale was disclosed in a legal filing with the SEC, which can be accessed through this link . Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $170.
49, for a total transaction of $99,395.67. Following the transaction, the chief technology officer now owns 10,424 shares in the company, valued at approximately $1,777,187.
76. This trade represents a 5.30 % decrease in their position.
The disclosure for this sale can be found here . 2.30% of the stock is owned by corporate insiders.
Inspire Medical Systems Profile ( Free Report ) Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. Further Reading Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. ( NYSE:INSP – Free Report ). Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.
com's FREE daily email newsletter ..
